Prevention and treatment of bacterial diseases caused by bacterial bioterrorism threat agents

Drug Discovery Today

Volumn 8, Issue 19, 2003, Pages 881-888

  Greenfield, Ronald A ^a   Bronze, Michael S ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Anthrax; Bioterrorism; Botulism; Drug Discovery; Microbiology; Pharmaceutical Science; Plague; Techniques Methods; Tularemia

Indexed keywords

ANTHRAX VACCINE; ANTIINFECTIVE AGENT; CHLORAMPHENICOL; CIPROFLOXACIN; DOXYCYCLINE; GATIFLOXACIN; GENTAMICIN; LEVOFLOXACIN; LIVE VACCINE; RECOMBINANT ANTIBODY; STREPTOMYCIN; TOXIN ANTIBODY; TULAREMIA VACCINE;

ANTHRAX; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACILLUS ANTHRACIS; BACILLUS CEREUS; BACILLUS SUBTILIS; BACTERIAL ENDOSPORE; BACTERIAL VIRULENCE; BIOLOGICAL WARFARE; BOTULISM; CLINICAL FEATURE; CLOSTRIDIUM BOTULINUM; DRUG EFFICACY; FRANCISELLA TULARENSIS; HUMAN; INFECTION PREVENTION; MICROBIAL SENSITIVITY TEST; NEPHROTOXICITY; OTOTOXICITY; PLAGUE; PLASMID; REVIEW; TOXEMIA; TULAREMIA; YERSINIA PESTIS;

ADJUVANTS, IMMUNOLOGIC; ANTHRAX; ANTI-BACTERIAL AGENTS; ANTITOXINS; BACTERIAL VACCINES; BIOTERRORISM; BOTULISM; HUMANS; INFECTION CONTROL; PLAGUE; TULAREMIA; VACCINES, DNA;

EID: 0141503524     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02847-2     Document Type: Review

References (56)

1. Inglesby T.V., et al. Anthrax as a biological weapon. Updated recommendations for management. Henderson D.A., et al. Bioterrorism. Guidelines for Medical and Public Health Management. 2002;63-97 American Medical Association Press.
2. Jernigan J.A., et al. Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States. Emerg. Infect. Dis. 7:2001;933-944.
3. Bartlett J.G., et al. Management of anthrax. Clin. Infect. Dis. 35:2002;851-858.
4. Bell D.M., et al. Conference summary: clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg. Infect. Dis. 8:2002;222-225.
5. Alibek K., Handelman S. Biohazard: The Chilling True Story of the Largest Covert Biological Weapons Program in the World. 1999;Random House.
6. Choe C., et al. In vitro development of resistance to ofloxacin and doxycycline in Bacillus anthracis Sterne. Antimicrob. Agents Chemother. 44:2000;1766.
7. Bryskier A. Bacillus anthracis and antibacterial agents. Clin. Microbiol. Infect. 8:2002;467-478.
8. 60Co γ-irradiated mice. Antimicrob. Agents Chemother. 46:2002;3463-3471.
9. Steigbigel N.H. Macrolides and clindamycin. Mandell G.L., et al. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 2000;366-382 Churchill Livingston.
10. Riedemann N.C., Ward P.A. Anti-inflammatory strategies for the treatment of sepsis. Expert Opin. Biol. Ther. 3:2003;339-350.
11. Friedlander A.M., et al. Postexposure prophylaxis against experimental inhalation anthrax. J. Infect. Dis. 167:1993;1239-1243.
12. Little S.F., et al. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect. Immun. 65:1997;5171-5175.
13. Kobiler D., et al. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive protection. Infect. Immun. 70:2002;544-550.
14. Casadevall A. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg. Infect. Dis. 8:2002;833-841.
15. Mourez M., et al. Designing a polyvalent inhibitor of anthrax toxin. Nat. Biotechnol. 19:2001;958-961.
16. Sellman B.R., et al. Dominant negative mutants of a toxin subunit: an approach to therapy of anthrax. Science. 292:2001;695-697.
17. Singh Y., et al. A dominant negative mutant of Bacillus anthracis protective antigen inhibits anthrax toxin action in vivo. J. Biol. Chem. 276:2001;22090-22094.
18. Schuch R., et al. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature. 418:2002;884-889.
19. Kournikakis B., et al. Anthrax-protective effects of yeast Beta 1,3 glucans. MedGenMed. 5:2003;1.
20. Friedlander A.M., et al. Anthrax vaccines. Curr. Top. Microbiol. Immunol. 271:2002;33-60.
21. Brachman P.S., et al. Field evaluation of a human anthrax vaccine. Am. J. Public Health. 52:1962;632-645.
22. Friedlander A.M., et al. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. J.A.M.A. 282:1999;2104-2106.
23. Maynard J.A., et al. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. 20:2002;597-601.
24. Flick-Smith H.C., et al. Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect. Immun. 70:2001;2022-2028.
25. Lee J.S., et al. Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge. Infect. Immun. 71:2003;1491-1496.
26. Guillemin J. Anthrax: the Investigation of a Deadly Outbreak. 1999;University of California Press.
27. Henderson D.W., et al. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J. Hyg. 54:1956;28-36.
28. Altboum Z., et al. Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs. Infect. Immun. 70:2002;6231-6241.
29. Jefferds M.D., et al. Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, D.C., 2001. Emerg. Infect. Dis. 8:2002;1138-1144.
30. Shepard C.W., et al. Antimicrobial post-exposure prophylaxis for anthrax: adverse events and adherence. Emerg. Infect. Dis. 8:2002;1124-1132.
31. Brookmeyer R., Blades N. Prevention of inhalation anthrax in the US outbreak. Science. 295:2002;1861.
32. Inglesby T.V., et al. Plague as a biological weapon: medical and public health management. J.A.M.A. 283:2000;2281-2290.
33. Smith M.D., et al. In vitro antimicrobial susceptibilities of strains of Yersinia pestis. Antimicrob. Agents Chemother. 39:1995;2153-2154.
34. Byrne W.R., et al. Antibiotic treatment of experimental pneumonic plague in mice. Antimicrob. Agents Chemother. 42:1998;675-681.
35. Crook L.D., Tempest B. Plague: a clinical review of 27 cases. Arch. Intern. Med. 152:1992;1253-1256.
36. Russell P., et al. The efficacy of ciprofloxacin and doxycycline against experimental tularaemia. J. Antimicrob. Chemother. 41:1998;461-465.
37. Kuberski T., et al. A case of plague successfully treated with ciprofloxacin and sympathetic blockade for treatment of gangrene. Clin. Infect. Dis. 36:2003;521-523.
38. Galimand M., et al. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. New Engl. J. Med. 337:1997;677-680.
39. Williamson E.D. Plague vaccine research and development. J. Appl. Microbiol. 91:2001;606-608.
40. Nierengarten M.B., Lutwick L. Vaccine development for plague. Medscape Infectious Diseases. 4:2002;2.
41. Williamson E.D., et al. A new improved subunit vaccine for plague-the basis of protection. FEMS Immunol. Med. Microbiol. 12:1995;223-230.
42. Friedlander A.M., et al. Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Clin. Infect. Dis. 21:(Suppl. 2):1995;S178-S181.
43. Heath D.G., et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine. 16:1998;1131-1137.
44. Grosfeld H., et al. Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigens. Infect. Immun. 71:2003;374-383.
45. Ellis J., et al. Tularemia. Clin. Microbiol. Rev. 15:2002;631-646.
46. Dennis D.T., et al. Tularemia as a biological weapon. Henderson D.A., et al. Bioterrorism: Guidelines for Medical and Public Health Management. 2002;167-189 American Medical Association Press.
47. Perez-Castillon J.L., et al. Tularemia epidemic in northwestern Spain: clinical description and therapeutic response. Clin. Infect. Dis. 33:2001;573-576.
48. Nierengarten M.B., Lutwick L. Developing new tularemia vaccines. Medscape Infectious Diseases. 4:2002;1.
49. Dreisbach V.C., et al. Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon. Infect. Immun. 68:2000;1988-1996.
50. Fulop M., et al. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine. 19:2001;4465-4472.
51. Surcel H.M., et al. Membrane proteins of Francisella tularensis LVS differ in ability to induce proliferation of lymphocytes from tularemia-vaccinated individuals. Microb. Pathog. 7:1989;411-419.
52. Sjostedt A., et al. Humoral and cell-mediated immunity in mice to a 17-kilodalton lipoprotein of Francisella tularensis expressed by Salmonella typhimurium. Infect. Immun. 60:1992;2855-2862.
53. Fulop M., et al. Role of two outer membrane antigens in the induction of protective immunity against Francisella tularensis strains of different virulence. FEMS Immunol. Med. Microbiol. 13:1996;245-247.
54. Arnon S.S., et al. Botulinum toxin as a biological weapon. Henderson D.A., et al. Bioterrorism. Guidelines for Medical and Public Health Management. 2002;141-165 American Medical Association Press.
55. Byrne M.P., Smith L.A. Development of vaccines for prevention of botulism. Biochimie. 82:2000;955-966.
56. Nierengarten M.B., Lutwick L. Vaccine development for botulism. Medscape Infectious Diseases. 5:2003;1.